Herbal based biodegradable scaffold and method of preparing thereof
Patent Information
- Application Number
- IN202641016040
- Authority / Receiving Office
- IN · IN
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2026-02-13
- Publication Date
- 2026-10-07
- Estimated Expiration
- 2046-02-13
AI Technical Summary
Conventional wound care products lack the combined anti-inflammatory, antimicrobial, and angiogenic activity necessary for accelerated and scarless healing, and existing delivery systems face challenges with stability, scalability, and regulatory compliance.
A biodegradable, biocompatible wound healing scaffold composed of polycaprolactone (PCL), Mallotus atrovirens plant extract, and quercetin dihydrate, fabricated via electrospinning, providing a synergistic composite that promotes antimicrobial, anti-inflammatory, and pro-angiogenic activity.
The scaffold accelerates wound closure with minimal scarring, supports tissue regeneration, and maintains bioactivity and structural integrity, suitable for large-scale manufacturing and medical-grade compliance.
Abstract
Description
Field of invention:(0001) The present invention relates to the field of biomedical materials and regenerative medicine, more particularly to advanced wound healing biomaterials. The invention pertains to a biodegradable polycaprolactone (PCL)-based scaffold and methods of fabrication. Background:(0002) Wound healing is a complex and highly regulated biological process involving inflammation, cell migration, angiogenesis, extracellular matrix remodeling, and tissue regeneration. Acute and chronic wounds resulting from trauma, surgery, burns, diabetes, and infections continue to pose a significant clinical burden worldwide. Conventional wound care products such as cotton gauze, basic polymeric dressings, and topical ointments primarily function as passive protective barriers and do not actively participate in the biological processes required for accelerated or scarless healing. As a result, delayed wound closure, infection, excessive inflammation, and fibrotic scar formation remain common clinical challenges. Conventional wound dressings, synthetic polymer scaffolds, and plant-based topical formulations provide basic coverage or limited antimicrobial protection but do not actively promote scarless healing. Most lack the combined anti-inflammatory, antimicrobial, and angiogenic activity necessary for accelerated tissue regeneration.(0003) To overcome these limitations, advanced wound dressings and tissue engineering scaffolds have been developed using natural and synthetic polymers, including collagen, gelatin, alginate, chitosan, and synthetic polyesters such as polycaprolactone (PCL). While natural polymers offer good biocompatibility and biological recognition, they often suffer from poor mechanical strength, batch-to-batch variability, limited shelf life, and difficulties in large-scale manufacturing. Synthetic polymers, on the other hand, provide superior mechanical stability, processability, and reproducibility, but are generally bioinert and lack intrinsic antimicrobial, anti-inflammatory, or pro-angiogenic properties necessary for effective tissue regeneration.(0004) In recent years, incorporation of bioactive compounds such as plant extracts and flavonoids into wound healing matrices has gained attention due to their antimicrobial, antioxidant, and anti-inflammatory effects. Compounds such as quercetin have demonstrated promising therapeutic potential; however, existing delivery systems often face challenges including poor stability, uncontrolled release, rapid degradation of bioactivity, and limited scalability. Moreover, many reported systems rely on non-medical-grade base materials or fabrication methods that are not compatible with regulatory requirements for clinical translation.(0005) Accordingly, there exists a clear and unmet need for a medical-grade, biodegradable, and scalable wound healing scaffold that combines the mechanical robustness of synthetic polymers with the multifunctional biological activity of natural bioactive agents. There is also a need for a composite system capable of promoting antimicrobial protection, inflammation control, angiogenesis, and scarless tissue regeneration, while maintaining long-term stability and compatibility with industrial manufacturing processes such as electrospinning. Hence, there is a need of developing plant based biodegradable composite scaffold that enhances wound healing.Objectives: (0006) The primary objective of the present invention is to develop a biodegradable, biocompatible, and medical-grade wound healing scaffold that promotes scarless tissue regeneration.(0007) Another objective is to develop a synergistic composite material comprising polycaprolactone (PCL), Mallotus atrovirens plant extract, and quercetin dihydrate, capable of delivering multifunctional therapeutic effects, including antimicrobial, anti-inflammatory, antioxidant, and pro-angiogenic activity.(0008) A further objective of the invention is to reduce dependency on adjunct therapies such as antibiotics or growth factors by incorporating intrinsic antimicrobial and angiogenic properties directly within the wound dressing material.(0009) Another objective of the invention is to provide a wound healing scaffold suitable for acute wounds, chronic wounds, post-surgical wounds, burns, and regenerative medicine applications, including tissue engineering and controlled drug delivery systems.Summary of the invention: (0010) The present invention relates to a biofunctional, biodegradable wound healing scaffold, and more particularly to a trimodal electrospun fibrous membrane comprising a polymeric matrix of poly(ε-caprolactone) (PCL) integrated with a plant-derived bioactive extract from Mallotus atrovirens and a flavonoid compound, quercetin dihydrate, for use in advanced wound healing applications.(0011) Conventional wound dressings and polymeric scaffolds are primarily passive in nature and generally lack the combined antimicrobial, anti-inflammatory, angiogenic, and regenerative functionalities required for accelerated and scarless wound repair. Many existing systems further suffer from poor mechanical stability, limited scalability, short shelf life, or lack of medical-grade compliance. The present invention addresses these limitations by providing a single, integrated scaffold that combines the structural and regulatory advantages of medical-grade PCL with the synergistic biological activities of Mallotus atrovirens extract and quercetin dihydrate.(0012) In accordance with the invention, the scaffold comprises a polymeric PCL matrix within which the plant extract and quercetin dihydrate are co-incorporated in defined proportions to form a homogeneous fibrous architecture. In one embodiment, the scaffold is fabricated by electrospinning, producing a porous, non-woven membrane that supports cell adhesion, migration, and tissue regeneration. The co-incorporation of the plant extract and quercetin dihydrate does not adversely affect their intrinsic physicochemical properties and enables sustained local availability of the bioactive components at the wound site.(0013) The scaffold of the present invention exhibits multifunctional therapeutic activity, including antimicrobial and antibiofilm effects, reduction of inflammatory response, promotion of angiogenesis, and enhanced epithelial regeneration, collectively resulting in accelerated wound closure with minimal or no scar formation. The scaffold is biocompatible, non-toxic, and biodegradable, thereby eliminating the need for removal after application.(0014) Experimental evaluations demonstrate that the scaffold promotes rapid wound healing and organized collagen remodeling, with reduced inflammatory markers compared to conventional wound dressings. The invention further provides a stable and scalable fabrication process, suitable for large-scale manufacturing without loss of bioactivity or structural integrity.(0015) The scaffold may be configured as a wound dressing membrane and is applicable to the treatment of acute and chronic wounds, post-surgical wounds, burns, and tissue injuries. In addition, the invention is suitable for use in regenerative medicine scaffolds, antimicrobial medical device coatings, and controlled drug delivery systems.(0016) Accordingly, the present invention provides a novel, medically compliant, and multifunctional wound healing scaffold that overcomes the deficiencies of existing wound care technologies and offers significant clinical and commercial advantages.Brief description of drawing:(0017) Fig 1: Schematic representation of Electrospun PCL membrane infused with Quercetin Dihydrate and Plant Extract(0018) Fig 2: FESEM image of biodegradable scaffold integrated with PCL.(0019) Fig 3: FESEM imaging revealed uniformly smooth fibrous structures with no bead formation, indicating homogeneous distribution of polycaprolactone, Mallotus atrovirens plant extract, and Quercetin dihydrate Plant extract and Quercetin dihydrate(0020) Fig 4: In vivo wound healing study evaluation on Sprague–Dawley rats(0021) Fig 5: Vascular responses in the HET-CAM assay. The positive control (NaOH) induced pronounced vascular haemorrhage; the negative control (NaCl) produced no observable effects. Scaffold integrated with PCL, Plant Extract and Quercetin dihydrate showed no signs of irritation or vascular haemorrhage.(0022) Fig 6: Qualitative detection of biofilm formation on Congo red agar, where the appearance of black colonies confirms biofilm-producing pathogenic isolates(0023) Fig 7 (a): Dose-dependent inhibition of biofilm formation by the test compound E.coli(0024) Fig 7 (b): Dose-dependent inhibition of biofilm formation by the test compound against P.aeruginosa (0025) Fig 7 (c): Dose-dependent inhibition of biofilm formation by the test compound against MRSA(0026) Fig 7 (d): Dose-dependent inhibition of biofilm formation by the test compound against S.aureus(0027) Fig 8: Photomicrographs of scar tissues subjected to H&E Staining under 40X magnification. The G3 has test sample and G4 has commercial band aid. The G3 and G4 sections showed areas of compact or irregular collagen deposition. G3 also preserves adnexal structures and demonstrates minimal fibroblast hyperproliferation, suggesting a regenerative process rather than purely reparative healing. (0028) Fig 9: Photomicrographs of scar tissues subjected to toluidine blue staining under 40X magnification(0029) FIG 10 (a): Photomicrographs of Gomori staining of (G3) show adnexal structures with less compactly arranged collagen fibres, showing true epithelization.(0030) FIG 10 (b): Photomicrographs of Gomori staining of (G4: Commercial band aid) show abundant collagen showing epithelization, but scar formation is in process(0031) FIG 11: Three-dimensional representation of wound healing outcomes across experimental groups.(0032) Fig 12: Bioactive Availability from the Scaffold: Release kinetics of the active ingredients.Detailed description: (0033) For the purposes of the present invention, the term “scaffold” refers to a biodegradable, biocompatible three-dimensional fibrous structure capable of supporting cellular adhesion, proliferation, migration, and tissue regeneration. The term “bioactive” refers to substances capable of eliciting a biological response, including antimicrobial, anti-inflammatory, angiogenic, and wound healing activity. The terms “comprising,” “including,” and “having” are intended to be inclusive and do not exclude additional components or steps.(0034) The present invention relates to the field of biomedical materials and regenerative medicine, more particularly to advanced wound healing biomaterials. The invention pertains to a biodegradable polycaprolactone (PCL)-based scaffold and methods of fabrication. Also the present invention discloses about a ‘Tri combination’ of composite of medical-grade PCL, Mallotus atrovirens extract, and quercetin dihydrate, which synergistically enhances scarless wound healing, outperforming conventional bandages by accelerating tissue regeneration while minimizing scar formation.(0035) The invention relates to developing a trimodal biofunctional biodegradable wound healing scaffold comprising, Poly(ε-caprolactone) (PCL) as a polymeric base matrix, a plant-derived bioactive extract obtained from Mallotus atrovirens; and a flavonoid compound comprising quercetin dihydrate. Wherein the plant extract and quercetin dihydrate are co-incorporated into the polymeric matrix to form an electrospun fibrous membrane. The invention integrates natural phytochemicals and flavonoids within a medical-grade synthetic polymer, producing a scaffold that provides synergistic antimicrobial, anti-inflammatory, angiogenic, and scar-reducing effects, leading to accelerated and scarless wound healing.(0036) The polymeric matrix used in the present invention comprises poly(ε-caprolactone), a biodegradable, semi-crystalline aliphatic polyester. PCL is selected due to its medical-grade purity (>99%), biocompatibility and biodegradability, mechanical flexibility and durability, suitability for electrospinning, regulatory acceptance for biomedical use. In one embodiment, PCL having a molecular weight of approximately 80,000 Da is used. However, other molecular weights suitable for electrospinning and wound healing applications may also be employed. The concentration of PCL in the electrospinning solution is preferably about 12 wt%, the concentrations ranging from 8–15wt%.(0037) The plant-derived bioactive component is obtained from leaves of Mallotus atrovirens, an evergreen tree belonging to the family Euphorbiaceae. The plant is known to contain phenolic compounds, flavonoids, xanthones, and organic acids, which exhibit antimicrobial, antioxidant, and anti-inflammatory properties.(0038) The flavonoid component comprises quercetin dihydrate. Quercetin dihydrate is incorporated into the polymeric matrix in a concentration of 1 wt% relative to PCL. The co-incorporation of quercetin dihydrate with the plant extract provides synergistic biological activity, enhancing wound healing outcomes beyond what is achievable with either component alone. The fabrication process ensures that the intrinsic physicochemical characteristics of quercetin dihydrate are retained following incorporation into the scaffold.Example 1: Preparation of Mallotus atrovirens Plant Extract(0039) Fresh, healthy leaves of Mallotus atrovirens were harvested from the herbal garden of Mar Athanasios College for Advanced Studies, Tiruvalla, Kerala, India. The leaves were collected during the morning hours and were visually inspected to ensure absence of disease or physical damage.(0040) Mallotus atrovirens Müll. Arg. is an evergreen tree belonging to the family Euphorbiaceae, native to the tropical regions of South and Southeast Asia, particularly the Western Ghats of India. The plant grows as a medium- to large-sized tree with simple, alternate, elliptic leaves and bears small, unisexual flowers arranged in axillary or terminal inflorescences. It produces capsule-like fruits, which are characteristically sour and traditionally used as a culinary condiment and natural preservative. Various parts of the plant, especially the fruits and leaves, are rich in bioactive phytochemicals including organic acids, flavonoids, phenolic compounds, and xanthones. These constituents contribute to its reported antimicrobial, antioxidant, anti-inflammatory, and therapeutic properties.(0041) The harvested leaves were washed thoroughly under running tap water followed by rinsing with distilled water to remove surface contaminants. The cleaned leaves were shade-dried at ambient room temperature for a period of approximately 72 hours to preserve thermolabile phytochemicals.(0042) After drying, the leaves were mechanically pulverized using a laboratory-grade grinder to obtain a fine powder. The powdered material was stored in airtight, chemically inert containers at room temperature until further use. From an initial raw biomass of approximately 995 g, about 30 g of dried powder was obtained.Example 2: Preparation of Electrospinning Solution(0043) Poly(ε-caprolactone) having an average molecular weight of approximately 80,000 Da was used as the polymeric base. About 1.2 g of PCL was dissolved in 10 mL of a binary solvent system comprising chloroform and acetone in a 1:1 weight ratio under continuous magnetic stirring.(0044) The solution was stirred until complete dissolution of the polymer was achieved. Subsequently, Mallotus atrovirens plant extract was added to the solution at a concentration of approximately 1 wt% relative to the polymer. Quercetin dihydrate was then added at 1 wt% relative to the polymer matrix.(0045) The resulting mixture was stirred at 30°C for 24 hours to obtain a homogeneous electrospinning solution containing uniformly dispersed bioactive components (as shown in fig 2 & 3).Example 3: Fabrication of Trimodal Electrospun Scaffold(0046) The homogeneous electrospinning solution prepared in Example 2 was transferred into a 10 mL plastic syringe fitted with a blunt 20-gauge stainless steel needle.(0047) Electrospinning was carried out using a direct current power supply with the parameters such as applied voltage: approximately 18 kV, flow rate: approximately 1 mL / h, needle-to-collector distance: approximately 15 cm and collector rotation speed: approximately 600 rpm. The fibers were collected on an aluminium foil-wrapped rotating collector, resulting in the formation of a uniform, porous electrospun membrane comprising PCL, Mallotus atrovirens extract, and quercetin dihydrate (as shown in fig 2 & 3).(0048) The homogenous mixture of PCL, Plant extract and Quercetin dihydrate is labelled as G3 and the commercial band-aid group is labelled as G4 for further experiments.(0049) The morphology of the electrospun scaffold was analyzed using field emission scanning electron microscopy (FESEM). The scaffold exhibited uniform, smooth, bead-free fibers, indicating homogeneous incorporation of the bioactive components.(0050) Structural characterization using X-ray diffraction (XRD) confirmed the retention of the semi-crystalline nature of poly(ε-caprolactone). Fourier transform infrared spectroscopy (FTIR) analysis confirmed the presence of characteristic functional groups corresponding to PCL, quercetin dihydrate, and phytochemical constituents of Mallotus atrovirens without chemical degradation.Example 4: In vitro scratch assay(0051) The in vivo evaluation in Sprague–Dawley rats demonstrated that the quercetin-infused plant extract patch (G3) supported effective wound healing with scarless tissue regeneration, as evidenced by hair regrowth at the wound site. The healing response observed in group G3 was comparable to and, in certain aspects, more favourable than that observed in (G4), as illustrated in the wound images. (G4) exhibited visible scar formation with no associated hair regeneration at the site of incision which is explained in Fig 4.(0052) No evidence of suppuration or adverse tissue response was observed in any group during the study period. Accelerated wound closure was observed in the quercetin-treated group, with pronounced epithelialization and wound contraction evident by day 8 and complete wound closure achieved by day 12. (0053) Histological evaluation using Gomori staining revealed collagen deposition of 71.1% in group G3 compared to 69.3% in the commercial band-aid group (G4). Toluidine blue staining further indicated enhanced epithelialization and angiogenesis with reduced polymorphonuclear cell infiltration, which was corroborated by H&E staining showing reduced inflammatory cell presence in the regenerated tissue, this was also documented by CRP-protein concentration which was 1.2ug / ml in (G3) and 1.9ug / ml in (G4) depicted in the table:1 below. Collectively, these findings demonstrate that the quercetin-infused plant extract scaffold provides effective wound healing with favourable inflammatory modulation when compared to a commercial wound dressing.Example 5: Antimicrobial Activity (0054) Biofilm inhibition was evaluated against MRSA, Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus at various concentrations of bioactive solution before fabrication. A clear concentration-dependent increase in biofilm inhibition was observed for all tested organisms, indicating effective antibiofilm activity in a dose-dependent manner. Data are presented as mean ± SD of independent experiments (n = 3). The experiments details are shown in figure 6 and the results are shown in figure 7 (a), (b), (c), and (d).Example 6: Anti-inflammatory, antimicrobial, and angiogenic activity (0055) Toluidine blue staining further corroborated the H&E findings, reinforcing the superior tissue response observed in G3. This section exhibited a uniform epidermal thickness without evidence of necrosis or parakeratosis, indicating complete epithelial restoration and functional barrier formation. In contrast, the fourth group G4 displayed focal epidermal thickening, areas of superficial necrosis, and residual parakeratosis, hallmarks of incomplete or aberrant healing. The absence of necrotic keratinocytes and the retention of normal keratin maturation in the G3 highlight reduced inflammatory stress and optimized keratinocyte turnover, aligning with the organized collagen remodelling observed in H&E staining. The data confirm that this treatment not only minimized dermal fibrosis but also restored epidermal homeostasis, thereby preventing pathological scar formation. The table inserted below demonstrates the comparable to marginally superior anti-inflammatory performance relative to a commercially available band-aid, as evidenced by biochemical inflammatory markers. Groups neutrophil (%) Lymphocytes(%) Eosinophil (%) Basophil (%) Monocytes (%) CRP (ug / mL) G3 12.80% 81% 2% 0 4% 1.2G4 11% 83% 2% 0 4% 1.9Table 1: Inflammatory markers post-treatment with the test scaffoldsGomori Staining (0056) The % area of collagen was calculated by digital densitometry in wound tissue sections stained by Gomori trichrome stain. This staining technique differentiates between tissue regeneration and fibrotic tissue formation. As collagen formation is a vital metabolism for robust epithelization, its distribution demonstrates whether the tissue modelling is optimistic or hypertrophic. Yellow arrow – collagen fibers, red circle- blood vessels, SL- stratum lucidum, SG- stratum granulosum, SC- stratum corneum, DP, dermal papillae, A - adipose tissue, S- sebaceous gland, ES- eccrine sweat gland, KC- keratin cyst, HF- Hair follicle as shown in fig 10. (0057) The plot as shown in Fig 11 illustrates the relationship between C-reactive protein (CRP) levels (µg / mL), wound healing score, and area of collagen deposition for different treatment groups (G1–G4). Each bar represents the mean value for the respective group, highlighting variations in inflammatory response (CRP), tissue repair (wound healing score), and collagen formation among the groups. G3 showing greater wound healing score, area of collagen and lesser C-reactive protein. (0058) The availability of the embedded plant extract and quercetin dihydrate from the fabricated scaffold was evaluated under physiological conditions to assess exposure of the bioactive constituents. The scaffold demonstrated a gradual diffusion of incorporated agents into the surrounding medium, with an initial low-level exposure followed by a stable release profile over the observation period. This behaviour is attributed to the homogeneous incorporation of the bioactive within the poly(ε-caprolactone) fibre matrix and the intrinsic porosity of the electrospun scaffold. The observed bioactive availability is sufficient to support localized antimicrobial and anti-inflammatory activity at the wound interface without rapid depletion of the active components, thereby enabling effective interaction with microbial contaminants and host tissue during the wound healing process as shown in fig 12. (0059) The present invention provides the following enhancement: • Provides Multifunctional Therapeutic Efficacy: The hybrid design integrating the tri-combination of PCL, Mallotus atrovirens and Quercetin dihydrate reduces the need for additional therapeutic interventions, as this provides significant biological functionality of natural compounds in a single material.• Integrates Bioactive Plant Extracts and Flavonoids: Incorporating Mallotus atrovirens and quercetin dihydrate imparts antimicrobial, anti-inflammatory, and angiogenic properties directly into the polymer scaffold.• Ensures Medical-Grade Purity: Using EN ISO 13485-compliant Polycaprolactone [PCL] ensures >99% purity, maintaining safety and reproducibility.• Enables Structural Versatility: The composite can be moulded, electrospun, or cast into various configurations for tailored biomedical applications.• Supports Large-Scale Production: The process is scalable without compromising quality or bioactivity, overcoming the limitation of small-batch laboratory methods.• Maintains Long-Term Stability: The composite retains physical integrity and bioactivity under varied storage and operational conditions.(0060) The commercial applications are as mentioned below:• Advanced wound care dressings for hospitals and home use.• Post-surgical dressings to accelerate healing and minimize scarring.• Regenerative medicine scaffolds for tissue repair and grafting.• Medical device coatings with antimicrobial and anti-inflammatory properties.• Pharmaceutical delivery systems, where controlled release of bioactive compounds is required.(0061) Technical effects of the invention are: • Accelerates wound closure and promotes scarless tissue regeneration.• Provides antimicrobial and anti-inflammatory effects, reducing infection risk and inflammation.• Supports angiogenesis, facilitating enhanced blood supply to healing tissue.• Biodegradable and non-toxic, eliminating the need for scaffold removal.• Can be moulded or electrospun into diverse configurations without loss of bioactivity.• Medical-grade reproducibility ensures consistent performance at scale.(0062) Utility of the invention of the invention are:• Wound care dressings for acute and chronic wounds.• Post-surgical dressings to accelerate healing and minimize scarring.• Tissue engineering scaffolds for regenerative medicine applications.• Antimicrobial coatings for medical devices.• Controlled drug delivery matrices integrating bioactive compounds.• Biodegradable sutures
Claims
1. A composition, comprising a polymer Polycaprolactone (PCL); a bioactive herbal extract; and flavonoid.
2. The composition as claimed in claim 1, wherein the bioactive herbal extract is extracted from Mallotus atrovirens.
3. The composition as claimed in claim 1, wherein the flavonoid is quercetin dihydrate.
4. The composition as claimed in claim 1 and claim 2, wherein the Mallotus atrovirens extract ranges from 1wt% of the PCL.
5. The composition as claimed in claim 1 and claim 3, wherein quercetin dihydrate ranges from 1wt% of the PCL.
6. The composition as claimed in claim 1, wherein the PCL; the Mallotus atrovirens and quercetin dihydrate are integrating through electrospinning to produce porous fibrous scaffold.
7. A method for infusing a polymer Polycaprolactone (PCL); a bioactive herbal extract; and flavonoid into scaffold comprises - blending of PCL and Mallotus atrovirens extract; - incorporating PCL, Mallotus atrovirens extract with Quercetin dihydrate; - homogenization of the mixture; and - electrospinning.
8. The method as claimed in claim 7, wherein the PCL and Mallotus atrovirens extract is dissolved in chloroform and acetone in ratio of 1:1 weight.
9. The method as claimed in claim 7, wherein the mixture of PCL, Mallotus atrovirens and Quercetin dihydrate is homogenized in 30°C for 24 hours through stirring.
10. The method as claimed in claim 7, wherein the electro spinning at 700 rpm using a collector wrapped in an aluminium substrate.
